US FDA approves Emergent’s smallpox vaccine for people at high risk of mpox

(Reuters) -The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions’ smallpox vaccine for use by people at high risk of mpox infection, sending the drugmaker’s shares surging 20% before the bell on Friday. The FDA clearance, announced late Thursday by the company, makes the vaccine, called ACAM2000, the second approved shot against…

Read More